COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment.
Identifieur interne : 000824 ( Main/Corpus ); précédent : 000823; suivant : 000825COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment.
Auteurs : Periklis VounotrypidisSource :
- Mediterranean journal of rheumatology [ 2529-198X ] ; 2020.
Abstract
The magnitude of the SARS-CoV-2 pandemic found health systems unprepared, not allowing for prompt evaluation, collaboration among specialities and treatment of severely ill patients admitted to intensive care units, with many of them having an unfortunate outcome. Current data demonstrate an acute immune dysregulation in severe forms of the disease. The above is concluded by clinical evolution and laboratory findings, indicating a severe inflammatory response of the innate immune system, initiating predominately with the involvement of the respiratory tract epithelial cells, occasionally progressing to thrombotic diathesis and related complications. Besides the clinical manifestations, the immune response expresses an extremely high acute phase reactants repertoire including hyperferritinemia, hyper-fibrinogenaemia, and a storm of cytokines that require an alternative view and collaboration with rheumatologists. Thrombotic diathesis in some cases may not attribute only to a possible disseminated intravascular coagulation, but also to an additional activation of adaptive immunity and the development of the antiphospholipid syndrome. Unifying speciality evaluation and treatment may improve patient outcomes by recognizing early the evolving syndromes, treating properly, in a stratifying manner, with medications that alleviate the inflammatory reaction. Corticosteroids, colchicine, hydroxychloroquine/chloroquine, and possibly potent immunosuppressants are in the armamentarium. Additionally, biologics that interrupt the innate immune dysfunction, such as IL-1, IL-6 and selective JAK inhibitors, are also used. Convalescent plasma therapy and human immunoglobulin may be restricted for those whom the proposed treatments are found inadequate. The above combined with antiretroviral medications may improve the outcome until the development of safe and effective vaccination.
DOI: 10.31138/mjr.31.3.275
PubMed: 33196005
PubMed Central: PMC7656129
Links to Exploration step
pubmed:33196005Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment.</title><author><name sortKey="Vounotrypidis, Periklis" sort="Vounotrypidis, Periklis" uniqKey="Vounotrypidis P" first="Periklis" last="Vounotrypidis">Periklis Vounotrypidis</name><affiliation><nlm:affiliation>Rheumatology Department, 424 General Military Hospital, Thessaloniki, Greece.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33196005</idno><idno type="pmid">33196005</idno><idno type="doi">10.31138/mjr.31.3.275</idno><idno type="pmc">PMC7656129</idno><idno type="wicri:Area/Main/Corpus">000824</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000824</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment.</title><author><name sortKey="Vounotrypidis, Periklis" sort="Vounotrypidis, Periklis" uniqKey="Vounotrypidis P" first="Periklis" last="Vounotrypidis">Periklis Vounotrypidis</name><affiliation><nlm:affiliation>Rheumatology Department, 424 General Military Hospital, Thessaloniki, Greece.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Mediterranean journal of rheumatology</title><idno type="eISSN">2529-198X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The magnitude of the SARS-CoV-2 pandemic found health systems unprepared, not allowing for prompt evaluation, collaboration among specialities and treatment of severely ill patients admitted to intensive care units, with many of them having an unfortunate outcome. Current data demonstrate an acute immune dysregulation in severe forms of the disease. The above is concluded by clinical evolution and laboratory findings, indicating a severe inflammatory response of the innate immune system, initiating predominately with the involvement of the respiratory tract epithelial cells, occasionally progressing to thrombotic diathesis and related complications. Besides the clinical manifestations, the immune response expresses an extremely high acute phase reactants repertoire including hyperferritinemia, hyper-fibrinogenaemia, and a storm of cytokines that require an alternative view and collaboration with rheumatologists. Thrombotic diathesis in some cases may not attribute only to a possible disseminated intravascular coagulation, but also to an additional activation of adaptive immunity and the development of the antiphospholipid syndrome. Unifying speciality evaluation and treatment may improve patient outcomes by recognizing early the evolving syndromes, treating properly, in a stratifying manner, with medications that alleviate the inflammatory reaction. Corticosteroids, colchicine, hydroxychloroquine/chloroquine, and possibly potent immunosuppressants are in the armamentarium. Additionally, biologics that interrupt the innate immune dysfunction, such as IL-1, IL-6 and selective JAK inhibitors, are also used. Convalescent plasma therapy and human immunoglobulin may be restricted for those whom the proposed treatments are found inadequate. The above combined with antiretroviral medications may improve the outcome until the development of safe and effective vaccination.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33196005</PMID><DateRevised><Year>2020</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2529-198X</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>Suppl 2</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Mediterranean journal of rheumatology</Title><ISOAbbreviation>Mediterr J Rheumatol</ISOAbbreviation></Journal><ArticleTitle>COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment.</ArticleTitle><Pagination><MedlinePgn>275-283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31138/mjr.31.3.275</ELocationID><Abstract><AbstractText>The magnitude of the SARS-CoV-2 pandemic found health systems unprepared, not allowing for prompt evaluation, collaboration among specialities and treatment of severely ill patients admitted to intensive care units, with many of them having an unfortunate outcome. Current data demonstrate an acute immune dysregulation in severe forms of the disease. The above is concluded by clinical evolution and laboratory findings, indicating a severe inflammatory response of the innate immune system, initiating predominately with the involvement of the respiratory tract epithelial cells, occasionally progressing to thrombotic diathesis and related complications. Besides the clinical manifestations, the immune response expresses an extremely high acute phase reactants repertoire including hyperferritinemia, hyper-fibrinogenaemia, and a storm of cytokines that require an alternative view and collaboration with rheumatologists. Thrombotic diathesis in some cases may not attribute only to a possible disseminated intravascular coagulation, but also to an additional activation of adaptive immunity and the development of the antiphospholipid syndrome. Unifying speciality evaluation and treatment may improve patient outcomes by recognizing early the evolving syndromes, treating properly, in a stratifying manner, with medications that alleviate the inflammatory reaction. Corticosteroids, colchicine, hydroxychloroquine/chloroquine, and possibly potent immunosuppressants are in the armamentarium. Additionally, biologics that interrupt the innate immune dysfunction, such as IL-1, IL-6 and selective JAK inhibitors, are also used. Convalescent plasma therapy and human immunoglobulin may be restricted for those whom the proposed treatments are found inadequate. The above combined with antiretroviral medications may improve the outcome until the development of safe and effective vaccination.</AbstractText><CopyrightInformation>© 2020 The Mediterranean Journal of Rheumatology (MJR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vounotrypidis</LastName><ForeName>Periklis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Rheumatology Department, 424 General Military Hospital, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Mediterr J Rheumatol</MedlineTA><NlmUniqueID>101730166</NlmUniqueID><ISSNLinking>2529-198X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">corticosteroids</Keyword><Keyword MajorTopicYN="N">disease-modifying anti-rheumatic drugs</Keyword><Keyword MajorTopicYN="N">hyperferritinaemia</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">rheumatology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>16</Day><Hour>8</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33196005</ArticleId><ArticleId IdType="doi">10.31138/mjr.31.3.275</ArticleId><ArticleId IdType="pii">MJR-31-Suppl-2-275</ArticleId><ArticleId IdType="pmc">PMC7656129</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ACR Open Rheumatol. 2020 May;2(5):283-285</Citation><ArticleIdList><ArticleId IdType="pubmed">32267072</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Nov 5;71(8):1937-1942</Citation><ArticleIdList><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jul;92(7):791-796</Citation><ArticleIdList><ArticleId IdType="pubmed">32181911</ArticleId></ArticleIdList></Reference><Reference><Citation>J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e362-e363</Citation><ArticleIdList><ArticleId IdType="pubmed">32378747</ArticleId></ArticleIdList></Reference><Reference><Citation>J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">32425269</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation><ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Cureus. 2020 Mar 20;12(3):e7343</Citation><ArticleIdList><ArticleId IdType="pubmed">32226695</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):e43</Citation><ArticleIdList><ArticleId IdType="pubmed">32294340</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mod Rheumatol. 2015 May;25(3):393-400</Citation><ArticleIdList><ArticleId IdType="pubmed">25382730</ArticleId></ArticleIdList></Reference><Reference><Citation>Interdiscip Top Gerontol Geriatr. 2020;43:1-17</Citation><ArticleIdList><ArticleId IdType="pubmed">32294641</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2020 Sep;159:104951</Citation><ArticleIdList><ArticleId IdType="pubmed">32464327</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Rheumatol. 2020 Aug;39(8):2379-2386</Citation><ArticleIdList><ArticleId IdType="pubmed">32130578</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2019 Dec 6;12:CD002243</Citation><ArticleIdList><ArticleId IdType="pubmed">31808551</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hematol. 2019 Jun;8(2):68-70</Citation><ArticleIdList><ArticleId IdType="pubmed">32300447</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Arthritis Rheum. 2015 Dec;45(3):341-50</Citation><ArticleIdList><ArticleId IdType="pubmed">26228647</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):854-887</Citation><ArticleIdList><ArticleId IdType="pubmed">32222812</ArticleId></ArticleIdList></Reference><Reference><Citation>J Emerg Med. 2006 Aug;31(2):185-99</Citation><ArticleIdList><ArticleId IdType="pubmed">17044583</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Klin Intensivmed Notfmed. 2020 May;115(Suppl 1):10-14</Citation><ArticleIdList><ArticleId IdType="pubmed">32291506</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2010 Aug;1800(8):760-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20304033</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2020 May 14;5:CD013600</Citation><ArticleIdList><ArticleId IdType="pubmed">32406927</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med J. 2020 Sep;96(1139):550-555</Citation><ArticleIdList><ArticleId IdType="pubmed">32295814</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jul;92(7):776-785</Citation><ArticleIdList><ArticleId IdType="pubmed">32297988</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Respir J. 2020 Jun 4;55(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">32269086</ArticleId></ArticleIdList></Reference><Reference><Citation>Mediterr J Rheumatol. 2020 Mar 31;31(1):94-97</Citation><ArticleIdList><ArticleId IdType="pubmed">32411941</ArticleId></ArticleIdList></Reference><Reference><Citation>High Alt Med Biol. 2020 Jun;21(2):192-193</Citation><ArticleIdList><ArticleId IdType="pubmed">32281877</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Iran Med. 2020 Apr 01;23(4):272-276</Citation><ArticleIdList><ArticleId IdType="pubmed">32271602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation><ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Rheumatol. 2020 Jul;39(7):2055-2062</Citation><ArticleIdList><ArticleId IdType="pubmed">32277367</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicine (Baltimore). 2018 May;97(19):e0595</Citation><ArticleIdList><ArticleId IdType="pubmed">29742693</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermatol Ther. 2020 Jul;33(4):e13639</Citation><ArticleIdList><ArticleId IdType="pubmed">32436617</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellenic J Cardiol. 2020 Jan - Feb;61(1):42-45</Citation><ArticleIdList><ArticleId IdType="pubmed">32251729</ArticleId></ArticleIdList></Reference><Reference><Citation>Signal Transduct Target Ther. 2020 Apr 28;5(1):57</Citation><ArticleIdList><ArticleId IdType="pubmed">32341331</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2020 Jun;145(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">32179660</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101623</Citation><ArticleIdList><ArticleId IdType="pubmed">32179124</ArticleId></ArticleIdList></Reference><Reference><Citation>J Emerg Med. 2017 Nov;53(5):653-661</Citation><ArticleIdList><ArticleId IdType="pubmed">28916121</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Rheumatol. 2020 Mar-Apr;38(2):175-180</Citation><ArticleIdList><ArticleId IdType="pubmed">32207680</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010 Feb 05;6(2):e1000756</Citation><ArticleIdList><ArticleId IdType="pubmed">20140198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 21;395(10228):e52</Citation><ArticleIdList><ArticleId IdType="pubmed">32171074</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2020 Aug;217:108487</Citation><ArticleIdList><ArticleId IdType="pubmed">32479986</ArticleId></ArticleIdList></Reference><Reference><Citation>ACR Open Rheumatol. 2020 May;2(5):276-282</Citation><ArticleIdList><ArticleId IdType="pubmed">32267081</ArticleId></ArticleIdList></Reference><Reference><Citation>J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e295-e297</Citation><ArticleIdList><ArticleId IdType="pubmed">32302437</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2020 Feb 14;11:207</Citation><ArticleIdList><ArticleId IdType="pubmed">32117318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autoimmun. 2008 Feb-Mar;30(1-2):84-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18191543</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386</Citation><ArticleIdList><ArticleId IdType="pubmed">32240123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellenic J Cardiol. 2017 Jan - Feb;58(1):93-95</Citation><ArticleIdList><ArticleId IdType="pubmed">28189738</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Med. 2020 May 14;9(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">32422983</ArticleId></ArticleIdList></Reference><Reference><Citation>Autoimmun Rev. 2020 May;19(5):102523</Citation><ArticleIdList><ArticleId IdType="pubmed">32205186</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Emerg Surg. 2018 Jan 25;13:6</Citation><ArticleIdList><ArticleId IdType="pubmed">29416555</ArticleId></ArticleIdList></Reference><Reference><Citation>Case Rep Med. 2016;2016:5656320</Citation><ArticleIdList><ArticleId IdType="pubmed">27688774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):400-402</Citation><ArticleIdList><ArticleId IdType="pubmed">32113509</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Res. 2020 Mar 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32184444</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Immunol. 2017 Oct;37(7):638-643</Citation><ArticleIdList><ArticleId IdType="pubmed">28871523</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 4;382(23):2268-2270</Citation><ArticleIdList><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 12;323(18):1775-1776</Citation><ArticleIdList><ArticleId IdType="pubmed">32203977</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2015 May 2;385(9979):1729-1737</Citation><ArticleIdList><ArticleId IdType="pubmed">25640810</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Signal Transduct Target Ther. 2020 Feb 21;5(1):18</Citation><ArticleIdList><ArticleId IdType="pubmed">32296012</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2020 Mar 16;24(1):91</Citation><ArticleIdList><ArticleId IdType="pubmed">32178711</ArticleId></ArticleIdList></Reference><Reference><Citation>Yale J Biol Med. 2020 Mar 27;93(1):187-195</Citation><ArticleIdList><ArticleId IdType="pubmed">32226347</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105932</Citation><ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):473-475</Citation><ArticleIdList><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2019 Feb;45(2):159-171</Citation><ArticleIdList><ArticleId IdType="pubmed">30706119</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Rheumatol. 2020 Apr;39(4):1363-1368</Citation><ArticleIdList><ArticleId IdType="pubmed">32088801</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Respir J. 2020 May 14;55(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicine (Baltimore). 2002 May;81(3):194-200</Citation><ArticleIdList><ArticleId IdType="pubmed">11997716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation><ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 23;382(17):e38</Citation><ArticleIdList><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 21;382(21):2012-2022</Citation><ArticleIdList><ArticleId IdType="pubmed">32227758</ArticleId></ArticleIdList></Reference><Reference><Citation>Tob Induc Dis. 2020 Mar 20;18:20</Citation><ArticleIdList><ArticleId IdType="pubmed">32206052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000824 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000824 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33196005
|texte= COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33196005" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |